Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update

Update of this US guidance now includes anastrazole as an option in postmenopausal women at increased risk. Tamoxifen 20 mg/day for 5yrs is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news